Stoke Therapeutics
STOK
26.81
-0.12
-0.45%
Stoke Therapeutics
US · STOK
#2942 by market cap
Listed 2019
26.81
-0.12
-0.45%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
TD Cowen Maintains Stoke Therapeutics(STOK.US) With Buy RatingMarket Newswire · 2026/5/8
-
Rating change
CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $60Market Newswire · 2026/3/20
-
Rating change
TD Cowen Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2026/10/13
-
Rating change
Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)TipRanks · 2026/8/4
-
Rating change
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $40 to $60Market Newswire · 2026/8/5
-
Rating change
J.P. Morgan Upgrades Stoke Therapeutics(STOK.US) to Buy Rating, Raises Target Price to $40Market Newswire · 2026/8/21
-
CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $58Market Newswire · 2026/11/3
-
Rating change
Goldman Sachs Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $44Market Newswire · 2026/10/6
-
Rating change
Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/8/4
-
Rating change
Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK), Genelux Corp. (GNLX) and Celldex (CLDX)TipRanks · 2026/5/9
-
Rating change
Guggenheim Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2026/5/8
-
Goldman Sachs Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Cuts Target Price to $43Market Newswire · 2026/10/30
-
Rating change
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/7/9
-
Rating change
Jefferies Initiates Stoke Therapeutics(STOK.US) With Buy Rating, Announces Target Price $44Market Newswire · 2026/7/14
-
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $39Market Newswire · 2026/11/2
-
Rating change
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $38 to $60Market Newswire · 2026/5/9
-
Rating change
Wedbush Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $38Market Newswire · 2026/3/18
-
Earnings Flash (STOK) Stoke Therapeutics, Inc. Reports Q3 Revenue $11.3M, Vs. FactSet Est of $8.2MMT Newswires · 2026/10/30
-
Rating change
Wedbush Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $38Market Newswire · 2026/3/17
-
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/11/3
-
Rating change
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/4/22
-
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $39Market Newswire · 2026/10/12
-
Rating change
CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $58Market Newswire · 2026/8/13
-
Rating change
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $40Market Newswire · 2026/3/17
-
Rating change
Wolfe Research Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $40Market Newswire · 2026/2/24
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Stoke Therapeutics discussion 0 comments